We are monitoring the impact of COVID-19 on Dermatitis Herpetiformis Market Get in touch with us for detailed analysis Know More
Pulished Date September, 2021
ID: 12186
Share on
Share on

Dermatitis Herpetiformis Market Segmentation By Therapeutics (Dapsone and Sulfapyridine), By Route of Administration (Topical and Oral); By Distribution channel (Pharmacies, Retail stores and E-Commerce) and Region - Industry Forecast of 2021 to 2026

Pulished: September, 2021
ID: 12186
Pages: 180

Dermatitis Herpetiformis Market Value & Growth Rate:

The Global Dermatitis Herpetiformis Market size was valued at US$ XX billion in 2021 and is anticipated to increase at US$ XX billion by 2026 and increase at a CAGR of XX% during 2021 and 2026.

Dermatitis Herpetiformis Market Scenario:

Dermatitis herpetiformis is a long-term autoimmune condition linked to gluten sensitivity. It's a rare condition that's tied to celiac disease. Dr. Duhring first described the ailment in 1884, and it is now known as Duhring disease or Duhring-Brocq disease. Erythematous, urticarial plaques, blisters, and pruritic vesicles are all symptoms of this condition. Knees, backs, scalps, elbows, and buttocks are the most common sites for these. The disease can be highly frustrating; however, sophisticated medical facilities and lifestyle changes have made dermatitis herpetiformis therapy possible. Dermatitis herpetiformis affects roughly 11.2 persons per 100,000 in the United States and 75.3 people per 100,000 worldwide. Hereditary and autoimmune factors complicate the disease's etiology. It causes sensitivity to the gluten protein gliadin, which is found in wheat, rye, and barley. Gluten in the diet causes immunoglobulin A antibodies, which initiate an autoimmune response against the skin and intestines. In dermatitis herpetiformis, gastrointestinal problems may or may not be symptomatic. Gluten-sensitive enteropathy is seen in about 90% of affected patients who have an endoscopic examination.

Dermatitis Herpetiformis Market Drivers:

The Global Dermatitis Herpetiformis Market growth is primarily due to the rapid increase in the number of cases of dermatitis herpetiformis. Moreover, patients between the ages of 15 and 40 may be affected. Males are more susceptible to the condition than females, according to the DermNet NZ organization. Dermatitis herpetiformis causes intense itching in patients. Manufacturers will be able to provide items that provide rapid comfort as a result of this. The global dermatitis herpetiformis market is bolstered by technological developments and rigorous research and development by scientists to improve medicine quality and reduce adverse effects. On the other hand, most of the world's population is more likely to have dental problems. Furthermore, dermatitis herpetiformis is frequently misdiagnosed as scabies. In addition, therapy medicines may cause anemia, type 1 diabetes, osteoporosis, and thyroid problems. Again, due to ongoing expenditures in developing treatments for dermatitis herpetiformis, the worldwide dermatitis herpetiformis market is estimated to rise rapidly in the near future.

Dermatitis Herpetiformis (DH) is a chronic autoimmune illness that causes severe itching and burning and a rash on the skin. It's most common in persons with celiac disease, a gluten-sensitive enteropathy, or a problem digesting gluten. In terms of epidemiology, DH is an uncommon disease that primarily affects young adults. It has been diagnosed in newborns as young as eight months old and elderly persons as old as ninety. Boys are more affected than females, with a 2:1 ratio. However, among patients under the age of 20, the ratio is 12 females for every eight men. The prevalence of DH varies by country, with 1:1,000,000 new cases per year in Germany, 11 cases per 100,000 in Scotland, 20-39 instances per 100,000 in Sweden, and 58.8 cases per 100,000 in Ireland. A strict gluten-free diet is a definitive treatment for DH, with skin improvement predicted in several months, albeit it may take years for the gluten-free diet to serve as the sole treatment.

Dermatitis Herpetiformis Market Restraints:

The global dermatitis herpetiformis market had significant consequences, and it is likely to be hampered by complications associated with the treatment of dermatitis herpetiformis.

Patients may, however, have dental problems. There's also a potential that dermatitis herpetiformis will be misdiagnosed as scabies. Furthermore, the patient has anemia, osteoporosis, Type 1 diabetes, and thyroid problems due to taking the therapeutic medicines. The global dermatitis herpetiformis market is being pushed by a lack of gluten-free food in some countries, an increase in the incidence of dermatitis herpetiformis, increased research and development of new treatment options, and more awareness.

Recent Developments in the Dermatitis Herpetiformis Market:

  • The USFDA has given Sun Pharma's subsidiary Taro preliminary approval to manufacture generic versions of Dapsone. Aczone is the brand name for this medicine, which Allergan sells.

  • Pfizer Inc. said today that the US Food and Drug Administration (FDA) had extended the priority review period for abrocitinib's New Drug Application (NDA) to treat moderate to severe atopic dermatitis in adults and adolescents. As a result, the Prescription Drug User Fee Act (PDUFA) deadline has been pushed back three months to early Q3 2021.

Dermatitis Herpetiformis Market Segmentation:

By Therapeutics:

  • Dapsone
  • Sulfapyridine

The dapsone medication segment is the most extensively utilized in Dermatitis Herpetiformis treatment. Dapsone treatment relieves skin symptoms fast and gives relief. Medical therapy with dapsone improves skin symptoms and provides symptomatic relief immediately. Other medicines, such as topical corticosteroids, are commonly used to treat Dermatitis Herpetiformis skin problems.

By Route of Administration:

  • Topical
  • Oral

The topical segment attributes the most significant global dermatitis herpetiformis market share during 2021-2026 and continues to hold the highest market share. A topical prescription drug is usually the first line of treatment for dermatitis herpetiformis. These can be in the shape of lotions, creams, suppositories, and other things. Such immediacy leads to speedy acquisition and substantial behavior maintenance, which is expected to drive segment growth in the market.

By Distribution channel

  • Pharmacies
  • Retail stores
  • E-Commerce

During the forecast period, the retail pharmacies category is expected to dominate. Medication for dermatitis herpetiformis is commonly available as a generic pharmaceutical in retail pharmacies. In addition, retail pharmacies provide convenient services such as medicine delivery to your home and the availability of a wide range of drugs and medicines. Furthermore, lipid-regulating medicines market expansion is expected to be boosted by consumer demand for quick availability of products due to busy lifestyles and stressful work schedules.

Dermatitis Herpetiformis Market Regional Analysis:

The Global Dermatitis Herpetiformis Market Report includes the segmentation of Regions:

  • Because of the increasing initiatives taken by pharmaceutical organizations to generate novel drugs, technological advancements, and a high adoption rate, North America is expected to dominate the global Dermatitis Herpetiformis market. This will help patients choose better treatment for Dermatitis Herpetiformis
  • On the other hand, due to increased inherited and genetic mutation-related illnesses, Europe is predicted to occupy the second-largest market share.
  • Due to low patient awareness, the dermatitis market in the Asia Pacific is likely to grow at a slower pace. However, the market is expected to grow throughout the forecast period due to increased R&D projects in Asian nations such as Japan and Australia, developing medical infrastructure, rising acceptance of technologically improved surgical techniques, and rising government initiatives.
  • Latin America
  • Middle East & Africa

Impact of COVID-19 on Dermatitis Herpetiformis Market:

The coronavirus (COVID-19) crisis and subsequent lockdown in several nations worldwide have impacted major urea cycle disorders treatment firms financially. Moreover, the private healthcare sector is one of the areas that the COVID-19 pandemic has most damaged. The pandemic has had a detrimental impact on the worldwide dermatitis herpetiformis market regarding research and development, production, and pharmaceutical supply. In addition, due to lockdowns imposed by governments in some countries, the pandemic has impacted the expansion of pharmaceutical industries of various corporations around the world.

Dermatitis Herpetiformis Market Key Players:

The companies covered in the report include:

  1. GlaxoSmithKline plc

  2. Allergan

  3. Valeant Canada LP

  4. Nostrum Laboratories Inc

  5. Pfizer Inc

  6. HBC Chem

  7. Shingles Skincare

  8. Anvia Chemicals

  9. Ivy Fine Chemicals

  10. Aidance Scientific

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Scope of the report                 

                1.3 Study Assumptions                 

                1.4 Base Currency, Base Year and Forecast Periods                           

2. Research Methodology                                           

                2.1 Analysis Design                         

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Data Modelling     

                                2.2.4 Expert Validation  

                2.3 Study Timeline                          

3. Report Overview                                        

                3.1 Executive Summary                

                3.2 Key Inferencees                       

4. Market Dynamics                                       

                4.1 Impact Analysis                        

                                4.1.1 Drivers      

                                4.1.2 Restaints 

                                4.1.3 Opportunities        

                4.2 Regulatory Environment                       

                4.3 Technology Timeline & Recent Trends                            

5. Competitor Benchmarking Analysis                                    

                5.1 Key Player Benchmarking                     

                                5.1.1 Market share analysis         

                                5.1.2 Products/Service 

                                5.1.3 Regional Presence

                5.2 Mergers & Acquistion Landscape                      

                5.3 Joint Ventures & Collaborations                        

6. Market Segmentation                                              

                6.1 Dermatitis Herpetiformis Market , By Therapeutics                   

                                6.1.1 Dapsone  

                                6.1.2 Sulfapyridine         

                                6.1.3 Market Size Estimations & Forecasts (2021-2026)   

                                6.1.4 Y-o-Y Growth Rate Analysis              

                                6.1.5 Market Attractiveness Index           

                6.2 Dermatitis Herpetiformis Market , By Route of Administration                             

                                6.2.1 Topical      

                                6.2.2 Oral            

                                6.2.3 Market Size Estimations & Forecasts (2021-2026)   

                                6.2.4 Y-o-Y Growth Rate Analysis              

                                6.2.5 Market Attractiveness Index           

                6.3 Dermatitis Herpetiformis Market , By Distribution channel                    

                                6.3.1 Pharmacies             

                                6.3.2 Retail stores           

                                6.3.3 E-Commerce          

                                6.3.4 Market Size Estimations & Forecasts (2021-2026)   

                                6.3.5 Y-o-Y Growth Rate Analysis              

                                6.3.6 Market Attractiveness Index           

7. Geographical Landscape                                         

                7.1 Global Identity Governance and Administration Market, by Region                    

                7.2 North America - Market Analysis (2021 - 2026)                            

                                7.2.1 By Country              

                                                7.2.1.1 USA

                                                7.2.1.2 Canada

                                7.2.2 By Therapeutics    

                                7.2.3 By Route of Administration              

                                7.2.4 By Distribution channel     

                7.3 Europe                         

                                7.3.1 By Country              

                                                7.3.1.1 UK

                                                7.3.1.2 France

                                                7.3.1.3 Germany

                                                7.3.1.4 Spain

                                                7.3.1.5 Italy

                                                7.3.1.6 Rest of Europe

                                7.3.2 By Therapeutics    

                                7.3.3 By Route of Administration              

                                7.3.4 By Distribution channel     

                7.4 Asia Pacific                  

                                7.4.1 By Country              

                                                7.4.1.1 China

                                                7.4.1.2 India

                                                7.4.1.3 Japan

                                                7.4.1.4 South Korea

                                                7.4.1.5 South East Asia

                                                7.4.1.6 Australia & NZ

                                                7.4.1.7 Rest of Asia-Pacific

                                7.4.2 By Therapeutics    

                                7.4.3 By Route of Administration              

                                7.4.4 By Distribution channel     

                7.5 Latin America                            

                                7.5.1 By Country              

                                                7.5.1.1 Brazil

                                                7.5.1.2 Argentina

                                                7.5.1.3 Mexico

                                                7.5.1.4 Rest of Latin America

                                7.5.2 By Therapeutics    

                                7.5.3 By Route of Administration              

                                7.5.4 By Distribution channel     

                7.6 Middle East and Africa                           

                                7.6.1 By Country              

                                                7.6.1.1 Middle East

                                                7.6.1.2 Africa

                                7.6.2 By Therapeutics    

                                7.6.3 By Route of Administration              

                                7.6.4 By Distribution channel     

8. Key Player Analysis                                    

                8.1 GlaxoSmithKline plc                

                                8.1.1 Business Description           

                                8.1.2 Products/Service 

                                8.1.3 Financials 

                                8.1.4 SWOT Analysis      

                                8.1.5 Recent Developments       

                                8.1.6 Analyst Overview 

                8.2 Allergan                       

                8.3 Valeant Canada LP                   

                8.4 Nostrum Laboratories Inc                     

                8.5 Pfizer Inc                     

                8.6 HBC Chem                  

                8.7 Shingles Skincare                     

                8.8 Anvia Chemicals                       

                8.9 Ivy Fine Chemicals                   

                8.10 Aidance Scientific                  

9. Market Outlook & Investment Opportunities                                 

Appendix                                           

                List of Tables                     

                List of Figures                   

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped

  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis

  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

  1. Global Dermatitis Herpetiformis Market By Region, From 2021-2026 ( USD Billion )

  2. Global Dermatitis Herpetiformis Market By Therapeutics, From 2021-2026 ( USD Billion )

  3. Global Dapsone Market By Region, From 2021-2026 ( USD Billion )

  4. Global Sulfapyridine Market By Region, From 2021-2026 ( USD Billion )

  5. Global Dermatitis Herpetiformis Market By Route of Administration , From 2021-2026 ( USD Billion )

  6. Global Topical Market By Region, From 2021-2026 ( USD Billion )

  7. Global Oral Market By Region, From 2021-2026 ( USD Billion )

  8. Global Dermatitis Herpetiformis Market By Distribution channel , From 2021-2026 ( USD Billion )

  9. Global Pharmacies Market By Region, From 2021-2026 ( USD Billion )

  10. Global Retail stores  Market By Region, From 2021-2026 ( USD Billion )

  11. Global E-Commerce Market By Region, From 2021-2026 ( USD Billion )

Please wait. . . . Your request is being processed

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample